develop revolutionari mrna therapi initi overweight target
develop messeng rna mrna new therapeut modal
drug elicit target endogen protein express treat broad rang
diseas compani advanc wholly-own merck-partn infecti
diseas cancer vaccin work astrazeneca cardiovascular diseas
compani wholly-own az-partn program intratumor oncolog
excit compani proprietari orphan diseas effort recent
rais million ipo hold estim pro forma cash billion
share ipo repres attract buy opportun
initi coverag overweight rate price target
prophylat cancer vaccin partner merck develop
infecti diseas cancer vaccin view vaccin lowest technic
risk novel mrna technolog importantli prophylact vaccin
safe administ individu initi proof-of-concept data report
compani influenza vaccin look multipl clinic start
year includ merck initi phase iia studi rsv vaccin
commenc phase ii immun studi cmv vaccin
women child-bear phase ib pediatr immun studi hmpv
vaccin perhap excit person cancer vaccin
pcv partner conduct phase trial
combin keytruda merck also initi phase studi
kras-mut tumor year
intratumor immuno-oncolog engin mrna therapeut
intratumor express cytokin potent stimul immun system
encod co-stimulatori factor activ monotherapi
two ovarian cancer patient advanc compris
mrna encod phase studi year
also partner astrazeneca intratumor therapi
orphan diseas develop four wholly-own mrna therapi treat
orphan diseas believ mrna technolog ideal suit address shortcom
enzym replac therapi ert increas half-lif extend dose
plan initi phase studi methylmalon academia mma
propion acidemia pa year
mrna therapeut novel could fail clinic gain approv
drug may reach sale forecast compani may invest project
develop innov mrna medicin
proj ev cash
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
coverag overweight rate price target
industry-lead messeng rna mrna compani develop pipelin
innov medicin found led sseason manag
team compani invest heavili sinc incept bioinformat oligonucleotid
chemistri deliveri technolog receiv signific invest fund
partner merck astrazeneca vertex overweight result effort
develop rich pipelin mrna medicin treat infectious diseas
cancer orphan diseas cardiovascular diseas date partner
advanc ten mrna vaccin therapi clinic last summer compani open
state-of-the-art mrna manufactur facil decemb complet largest biotech
ipo histori rais gross proce million bring pro forma cash billion
see unicorn potenti becom cap compani
sever approv mrna medicin treat wide rang diseas
first clinic program prophylact infecti diseas vaccin view
vaccin repres lowest technic risk novel mrna technolog importantli
prophylact vaccin safe administ individu initi proof-of-concept
clinic data report compani influenza vaccin two addit
phase studi rsv chikungunya vaccin gener neutral antibodi
protect level look multipl clinic start year includ merck initi phase iia
studi rsv vaccin commenc phase ii immun studi cmv
vaccin women child-bear phase ib pediatr immun studi
also co-develop two clinical-stag cancer vaccin profit share
agreement merck perhap excit person cancer vaccin base
tumor sequenc select individu antigen like induc
immun respons partner conduct phase trial sign
activ combin keytruda merck plan random phase
ii trial combin data merck also plan initi phase studi mrna-
kras-mut tumor year
separ engin mrna therapeut intratumor express cytokin
potent stimul immun system encod co-stimulatori factor
activ monotherapi two ovarian cancer patient advanc mrna-
compris three mrna encod phase studi
year also partner astrazeneca intratumor therapi
develop four wholly-own mrna therapi treat orphan diseas believ
mrna technolog ideal suit address shortcom enzym replac therapi
ert increas half-lif extend dose initi phase studi
methylmalon academia mma propion acidemia pa year
enter sever valid partnership astrazeneca partner
develop mrna therapi cardiovascular metabol diseas az conduct phase ii
studi vegf-a cabg patient januari merck enter collabor
develop prophylact vaccin rsv chicken pox two undisclos virus
merck expand allianc develop pcv last may includ kra
vaccin june vertex enter collabor develop mrna
therapi produc function cftr protein cystic fibrosi patient
page
partner develop mrna medicin classifi pipelin five
intratumor immuno-oncolog therapi orphan diseas cardiovascular diseas
astrazeneca partner cardiovascular program merck infecti diseas
cancer vaccin also receiv fund darpa barda nih
viral infect propag host cell rna-medi express viral protein
moderna mrna vaccin encapsul lipid nano particl lnp taken
immun cell vaccin mimic natur process immun
system recogn infect multipl mrna transcript includ singl
vaccin moderna cmv vaccin compris six mrna transcript bolster
immun protect design manufactur synthet mrna vaccin fast could
enabl rapid respons public health threat like zika pandem influenza
develop nine prophylact vaccin seven enter clinic
importantli prophylact vaccin safe administ
individu four mrna candid achiev seroconvers level indic
therapeut benefit includ vaccin two differ flu strain rsv chikungunya
partner merck rsv vaccin chicken pox vaccin mrna-
look multipl clinic start year includ merck initi phase iia studi
commenc phase ii immun studi cmv vaccin
women child-bear phase ib pediatr immun studi hmpv vaccin
receiv barda fund zika vaccin seek
extern fund advanc flu vaccin well chikungunya
page
adult
escal
safeti
protect
protect
potenc
merck
low-teen
owe
billion
studi
transfer ind
subject
digit low-
teen net
subject
subject
page
build prophylact vaccin program develop two clinical-stag cancer
vaccin partner merck person cancer vaccin specif
engin base sequenc inform patient tumor compris
individu antigen order illicit broadest target immun respons
shown monotherapi activ advanc solid tumor patient remain disease-fre
post-op differenti neoantigen approach shown
singl agent activ merck combin keytruda on-going
studi could extend durat respons earli data show
vaccin ad keytruda gener partial respons patient stabl
diseas checkpoint refractori patient dose merck plan random phase
ii trial combin data
kra proven undrugg target small molecul unabl bind
multipl variant shallow alloster site contrast inhibit knockdown mutant kra
protein mrna vaccin encod multipl antigen illicit immun respons
sever kra variant approach refin select patient
particular hla type order enhanc anti-tumor activ expect studi start
transfer ind merck expect initi phase studi kras-mut
tumor year pleas exhibit
pr sd
studi
merck
studi
owe
design therapeut intratumor inject potent stimul immun respons
immunolog cold tumor tumor harbor immune-suppress microenviron
devoid checkpoint-express t-cell diminish efficaci
antibodi design mrna inject intratumor encod cytokin
stimul local immun respons well co-stimulatori t-cell agonist expand
popul effector t-cell promot memory-lik respons first candid
encod t-cell co-stimul show monotherapi activ abscop effect
two ovarian cancer patient data offer proof-of-concept ultim expect mrna-
compris three mrna advanc build
effector cell activ mediat pro-inflammatori cytokin
may induc local innat respons turn immunolog cold tumor hot strategi
would complement combin approach checkpoint inhibitor antibodi enhanc
durabl respons expect phase start next year evalu monotherapi
checkpoint inhibitor combin refractori solid tumor patient partner
astrazeneca advanc phase solid tumor studi pleas exhibit
page
regress
cohort
studi
transfer
az begin
studi
profit share
ex-u net
develop pipelin wholly-own mrna candid treat orphan diseas
mrna therapi endogen express protein defici rare genet disord
believ mrna therapi could address shortcom enzym replac therapi ert
includ increas half-lif extend dose gene therapi gene edit offer potenti
solut orphan genet diseas still carri risk insert mutagenesi may
slow clinic advanc especi children initi phase studi mrna-
methylmalon academia mma file ind propion acidemia pa
phenylketonuria pku year also develop
treat fabri diseas pleas exhibit expect name sever new
orphan diseas program next sever year
ind file
phase i/ii start
mut-
ind file
phase i/ii start
file ind
start
file ind late
page
astrazeneca develop two mrna candid cardiovascular diseas phase studi
demonstr dose-depend increas vegf-a earli sign improv heart
function az conduct phase iia studi az also develop relaxin
mrna phase studi start anticip pleas exhibit
singl digit
owe
merck initi phase iia rsv studi
complet phase part dose escal begin phase ii immun studi
women child-bear age
complet ind-en glp tox studi transfer ind merck
complet ind-en glp tox studi zika vaccin
flu vaccin advanc subject fund
report full phase data chikungunya vaccin advanc subject fund
complet phase pcv dose escal expans merck begin
random control phase ii studi solid tumor initi data
nci report phase investigator-sponsor pcv data
ind transfer merck phase monotherapi keytruda combin
studi begin
complet phase dose expans phase ii cohort ovarian cancer
initi phase studi monotherapi combo
transfer packag astrazeneca begin phase monotherapi combin
studi
ind file phase i/ii start mma mut-defici pediatr
ind file phase i/ii start pa pediatr patient
file ind phase sad studi start pku
file ind fabri diseas
partner astrazeneca complet phase iia enrol ischem heart failur
patient undergo cabg surgeri report data possibl
complet ind-en glp toxicolog studi transfer packag
astrazeneca initi phase studi heart failur patient
page
initi coverag overweight rate price target base
project enterpris valu billion plu cash complet ipo
decemb share repres attract buy
opportun view
valu wholly-own cmv vaccin million appli standard
multipl sale billion discount back valu wholly-
own vaccin million appli multipl sale
billion discount back view discount rate
appropri phase vaccin valu merck-partn rsv vaccin
million appli multipl royalti million discount back
view multipl appropri higher margin royalti
discount rate appropri phase ii-readi vaccin add million moderna
influenza vaccin zika vaccin
chikungunya vaccin
partner merck develop person cancer vaccin valu
billion addit valu merck-partn kra vaccin million
appli multipl share sale million discount back
view discount rate appropri ind-readi cancer vaccin
add million valu wholly-own intratumor ovarian cancer
valu wholly-own intratumor melanoma
tripl neg breast cancer billion appli multipl sale
billion discount back view discount rate appropri
ind-readi intratumor cytokin therapi add million az-partn preclin
valu wholly-own methylmalon acidemia mma billion
appli multipl sale billion discount back
valu wholly-own propion acidemia pa million appli
multipl sale million discount back valu wholly-
own phenylketonuria pku million appli multipl
sale billion discount back view
discount rate appropri ind-readi orphan diseas program add million
wholly-own preclin fabri diseas
astra-zeneca develop myocardi ischemia valu million
appli multipl royalti million discount back
view multipl appropri higher margin royalti discount rate
appropri phase ii intra-myocardi mrna program add million az-partn
preclin heart failur
end cash billion subsequ issu million
share rais gross proce million estim hold pro
forma cash billion million share outstand thu add estim
net cash billion divid project market cap billion million
share arriv price target pleas see exhibit
page
page
applic rna novel therapeut modal mediat protein express deriv
directli central dogma biolog first publish franci crick process
articul flow biolog inform dna rna protein double-strand dna
store genet inform everi live cell form nucleotid adenin guanin
cytosin thymin transcript dna nucleotid produc complementari single-
strand messeng rna mrna strand like call mrna softwar life
mrna translat ribosom complex seri amino acid serv
build block protein protein subsequ undergo post-transl fold
modif form function protein pleas exhibit
central dogma biolog
emerg
last three decad rna medicin emerg new therapeut class nucleic
acid therapeut first conceiv experi conduct wolff et al
demonstr vivo gene transfer rna dna construct skelet mous muscl
result protein express compar vitro transfect scienc
howev industri initi pursu dna-bas construct believ rna
hard work rna larg hydrophob molecul inher unstabl prone
degrad rnase cytoplasm nake rna transcript induc immun
respons properti present uniqu hurdl rna therapeut applic
technolog advanc enhanc stabil safeti potenc deliveri rna
therapeut fact nobel prize award dr andrew fire craig mello
discoveri rna-interfer rnai sinc recogn shift rna drug
discoveri effort begin translat clinic regulatori success rna
medicin receiv fda approv clearli leader antisens oligonucleotid aso
chemistri ioni van buren first gain approv vitraven cmv retin
immunocompromis aid patient partner novarti kynamro treat homozyg
famili hypercholesterolemia genzyme/sanofi spinraza treat spinal
muscular atrophi raymond also year sarepta
overweight gain approv exon skip therapi exondi treat duchenn
muscular dystrophi last year alnylam overweight gain approv first rnai
therapeut onpattro ioni gain approv tegsedi treat hereditari ttr
page
advantag
pseuodouridin
despit acceler recent approv still earli inning rna therapeut
develop howev see broaden applic rna technolog four
primari subtyp rna therapeut aso rnai microrna mrna aso rnai
therapi class receiv fda approv believ rapidli
advanc field deliv addit drug includ mrna medicin
mrna uniqu rna therapeut modal abil directli synthes target
protein use exist cellular machineri synthet mrna theoret express protein
includ antibodi thu treat virtual diseas rnai work specif downgrad
silenc target rna aso microrna induc splice variant induc exon
skip express certain protein approach primarili inhibit express diseas
anoth major point contrast length molecul mrna far longest
measur nucleotid enabl express full-length protein even
multipl sequenc concatem continu nucleotid strand aso rnai
microrna gener rang nucleotid length number nucleotid
requir select target across entir human genom
mrna protein express catalyt mechan one molecul translat
hundr thousand time properti allow low dose could
favor safeti implic allow less frequent administr
optim safeti efficaci mrna vaccin therapi highli engin
molecul specif compani design site-specif modif nativ single-
strand rna molecul increas stabil decreas immunogen enhanc translat
effici develop proprietari deliveri system includ lipid
nanoparticl lnp reduc degrad nake rna cytoplasm increas uptak
target cell much work publish genom medicin kaczmarek et al
importantli invest heavili manufactur optim
process abl make sophist molecul scale
mrna stabil key improv translat effici increas protein product
stabil enhanc codon optim modif mrna
end guard subsequ transcript degrad codon optim process
switch rare codon abund codon without chang amino acid sequenc
order increas translat effici amend cap poli tail includ
new type cap analog base pair poli tail improv express
capit decad research elucid mechan
rna activ human innat immun system improv mrna therapi immun
respons serv protect higher organ pathogen rna virus howev
design mrna therapi requir specif modif blunt immun activ toll-lik
receptor tlr rig-i associ detect pathogen rna specif
detect doubl strand rna detect singl strand rna uridin
one four rna nucleotid shown associ innat immun
stimul base evid gener experi replac base
page
kariko et al publish semin find show substitut natur occur
modifi nucleotid pseudouridin uridin result tlr activ vitro
weissman et al immun kariko et al also reproduc find vivo
model show pseudouridin substitut suppress mrna-medi immun
stimul also enhanc translat effici rna kariko et al mol ther
find essenti advanc mrna novel
derrick rossi co-found associ professor stem cell regen
biolog harvard medic school show substitut cytidin
addit pseudouridin uridin work even better doubl substitut offer superior
transcript viabil increas protein express compar either substitut alon
interferon signal broadli downregul respons modif well
particular experi synthet mrna use drive differenti ipsc
termin differenti cell impress viabil warren et al cell stem cell
novemb import take-away method mrna
synthes implement anti-vir properti applic outsid cell program
area vaccin therapeut drug develop
make modif rna improv therapeut function new sirna
aso make ribos phosphat modif respect uridin backbon
achiev mrna alter thwart translat demonstr
previous describ experi nucleotid substitut impact translat effici
actual enhanc
specif found modif reduc
immun stimul increas translat effici modif disrupt
thermodynam favor bond uridin hoogsteen face substitut
modifi uridin base pair interrupt energet prefer pi-stack face
result absenc innat immun stimul confirm effect
novel chemistri vitro vivo experi pleas exhibit
also make modif facilit format secondari structur necessari
step form complet function protein modifi codon sequenc
proprietari sequenc engin enhanc fidel ribosom bind
correct start codon subsequ initi translat build upon work dr
melissa moor ph serv chief scientif offic research platform
sinc dr moor extens research rna protein structur regulatori
page
mechan identifi protein bind doubl strand rna encourag
secondari structur format enhanc activ ribosom ricci et al struct mol
biol particular protein shown optim protein
translat tether end mrna dugre-brisson et al nucleic acid
dr moor appli expertis make translat output
reliabl also optim codon sequenc express commonli occur codon
higher likelihood produc secondari structur pleas exhibit
optim codon sequenc contain mrna influenc secondari structur
modif mrna transcript describ improv therapeut potenti
mrna molecul deliveri mrna also critic therapeut effect rna
deliv viral non-vir nanoparticl viral-medi deliveri remain
attract area research especi use adeno-associ virus approach
carri risk immunogen random insert mutagenesi non-vir strategi
emerg altern approach lipid nanoparticl lnp becom wide
adopt non-vir modal eas formul reliabl oligonucleotid encapsul
abil dose system lower immunogen risk new modif lnp
increas cellular uptak endosom escap translat therapeut efficaci fact
fda approv alnylam onpattro first-ev lnp-encapsul rnai
lnp formul order structur electrostat hydrophob interact
four critic compon amino lipid phospholipid cholesterol peg-lipid term
formul mix mrna cargo aqueou buffer lipid ethanol provid
charg interact drive encapsul mrna particl regard efficaci
amino lipid core compon respons regul cellular uptak endosom escap
toler cholesterol peg-lipid modul stabil shelf-lif white phospholipid
facilit cell fusion cargo uptak sabni et al mol ther
efficaci depend upon inclus cation ioniz lipid posit charg
acid environ thought specif chemic properti associ help
endosom escap reduc toxic kaczmarek et al
design proprietari lnp optim four foundat
compon significantli improv efficaci toler construct
librari chemic divers lipid select optim therapeut characterist use high
throughput screen proprietari lnp technolog contain ethanolamin amino lipid head
group ester linkag posit precis locat lipid tail ethanolamin
determin effici head group reduc immunogen increas protein
page
express compar tradit lnp approach rat model select
posit ester linkag facilit vivo tissu clearanc non-human primat nhp
sabni et al combin head group ester linkag optim protein
express lipid clearanc pleas exhibit
proprietari lnp increas protein product rat rapidli clear nhp
endosom escap effici also improv lnp design lnp interact
target cell endocytosi allow mrna cargo reach cell cytoplasm escap
transcript effici proprietari lnp result escap effici
compar lnp therefor increas mrna deliv cell
augment protein express one-month toxicolog studi rat non-human primat
confirm advers event sabni et al
importantli alter pharmacokinet profil faster clearanc impact weekli iv
dose schedul vivo nhp studi addit modifi amino lipid ester linkag
phospholipid tail also engin unstabl rapidli shed
surfac lnp time interact biolog target modif dramat
alter pharmacokinet profil lnp reduc rate vivo clearanc perhap
enhanc effici endosom escap sabni et al demonstr remark
predict pharmacolog modifi lnp ethanolamin head group primari ester-
contain lipid tail repeat dose experi nhp mrna encod human epo
administ iv mg/kg dose weekli week pleas exhibit
weekli dose mrna hepo proprietari lnp reliabl pharmacolog
first program incorpor proprietari lnp encod antibodi
chikungunya viru data ind-en nhp studi show linear dose-respons
increas mrna correspondingli antibodi highlight predict
pk design proprietari lnp design pleas exhibit
page
rapid clearanc proprietari lnp nhp increas protein product rat
also made edit control mrna express cell type
minim off-target effect enhanc therapeut safeti profil microrna mirna small
non-cod molecul bind complementari region mrna silenc neg
regul post-transcript gene express via antisens mechan mirna cell
diseas specif capit mirna express pattern control mrna
activ select cell type exampl healthi hepatocyt high concentr
cancer cell known significantli reduc express mirna
took advantag known biolog engin perfectli complementari
sequenc region mrna therapeut also
encod apoptot protein liver enzym assay vivo xenograft mous model
show healthi cell surviv follow exposur mrna incorpor complementari mirna
sequenc indic mirna-medi degrad prevent apoptot protein express
find publish jain et al nucleic acid pictur
exhibit approach enabl sophist control system deliveri
mrna move beyond enhanc lnp local inject
express mirna normal vs tumor cell reduc off-target mrna effect
page
mrna creat use cell-fre approach call vitro transcript rna
polymeras elong rna strand dictat templat dna process improv
precis involv transcript rna strand expedit product fact
manufactur new mrna molecul per month scale meet
requir preliminari anim studi
invest heavili better understand physic interact lnp assembl
purif lnp self-assembl electrostat interact neg charg
oligonucleotid result particl encapsul result product purifi remov
unincorpor compon mrna could unfavor stimul immun system
juli open state-of-the-art mrna manufactur facil norwood
massachusett compani invest million squar ft facil goal
ultim produc mrna clinic scale lot everi year facil held clinic
manufactur practic cgmp standard capac complet preclin
toxicolog test manufactur mrna and/or lnp phase ii clinic studi raw
materi complet run fill/finish oper norwood also design unit suppli
person cancer vaccin pcv expect manufactur facil
acceler number development candid clinic trial start
built impress patent estat issu allow foreign patent
novemb bulk patent relat proprietari platform
includ broad method claim cover mrna synthesi lnp product encapsul
mrna also patent issu composit proprietari lnp
development candid mrna sequenc level encod antigen
addit patent applic foreign patent applic pend
major patent expir earliest recent file patent
page
concept mrna
believ prophylact vaccin logic first modal repres lowest
technic risk novel mrna technolog importantli prophylact vaccin
safe administ individu initi proof-of-concept clinic data report
compani influenza vaccin two addit phase studi rsv
chikungunya vaccin gener neutral antibodi look multipl clinic start
year includ merck initi phase iia studi rsv vaccin
commenc phase ii immun studi cmv vaccin women child-
bear phase ib pediatr immun studi hmpv vaccin
influenza viru surfac coat made influenza influenza protein among
signific hemagglutinin neuraminidas type differ flu
strain base identif protein subtyp coat protein present
target bodi immun system effect influenza prevent strategi
prophylact vaccin gener neutral antibodi specif strain
howev develop broadli effect season flu vaccin challeng
antigen drift current slow manufactur process antigen drift caus
accumul mutat antibody-bind site render flu vaccin less potent time
retrospect analysi adult vaccin virul strain
season show consist lower protect regardless age russel et al vaccin
feb flu season vaccin efficaci adult
egg-bas flu vaccin current repres market howev
manufactur approach minim efficaci flu virus modifi grow chicken
egg subsequ passag egg result mismatch lab grown viru
circul season viru potenti diminish vaccin benefit addit peopl
allerg egg administ vaccin
first achiev proof-of-concept show lnp-encapsul mrna
vaccin capabl gener rapid immun low dose favor safeti
toler design avian flu viru strain sinc human
expos viru serv ideal first proof concept target get
unbias view immun respons mrna vaccin
initi report china decemb three patient becam infect
strain experienc sever pneumonia subsequ acut respiratori distress syndrom
patient die day hospit third case sever cdc
though case report limit real-world world evid suggest infect
result sever symptom even fatal
evalu immunogen two lnp-encapsul mrna transcript encod
ha mice ferret nhp hai
titer measur singl inject either mrna mice statist
signific increas titer observ day durabl day intramuscular
intraderm administr produc similar level immun protect re-challeng lethal
influenza show previous vaccin mice significantli increas surviv compar
non-vaccin control compar singl immun either
exhibit strong titer induct durabl nhp studi highest dose caus
minor inject site reaction sae observ
page
phase iia studi
preclin activ translat clinic proof-of-concept phase studi mrna-
april report interim result subject
immunogen data demonstr stark contrast efficaci produc
protect antibodi titer hai microneutr
subject compar receiv placebo impress vaccin hai
level baselin compar placebo group well-toler
report three case includ injection-sit reaction common cold-lik
symptom revers compar flu vaccin result publish
also conduct phase studi deadli avian flu strain
futur develop incumb govern fund
merck develop season vaccin respiratori
syncyti viru rsv rsv preval season infect caus respiratori tract
infect rsv common caus lower respiratori tract infect children global
account infect patient age resch et al vaccin
immunoth rsv also affect elderli estim
hospit american death annual accord cdc rsv season
extend month peak late decemb mid-februari
synagi palivizumab fda-approv therapi prevent rsv high-risk infant
synagi monoclon antibodi rsv fusion protein develop
medimmun approv base statist signific lower rsv hospit
treat subject versu placebo arm pediatr
howev five monthli intramuscular inject burdensom physician
wide question cost-benefit synagi per cours treatment synagi
approv older adult avail rsv therapi astrazeneca sold
right synagi swedish orphan biovitrum sobi
overweight develop advanc rsv-f vaccin resvax
anticip phase prepar matern immun data resvax novavax rsv-f
vaccin fail prior phase trial elderli individu
encod stabil pre-fusogen protein f-protein highli conserv
critic viruss abil infect cell substanti structur chang f-protein occur
throughout infect target pre-fusogen epitop may elicit strongest neutral
phase studi healthi adult subject met endpoint safeti
toler show neutral antibodi titer rsv healthi volunt part
assess three dose level younger subject year part evalu four dose
level older subject year three dose induc neutral antibodi
titer rsv rsv younger adult first two cohort older adult show
dose-depend induct neutral titer respons appear durabl although await
day data third highest dose level pleas exhibit compet
antibodi titer rsv prefus protein also observ dose-depend manner
first two cohort younger older subject well-toler dose
level popul fourth dose level older adult least toler
drug-rel sae discontinu base interim phase data merck plan
begin phase iia studi
page
produc neutral antibodi titer rsv phase studi
rsv awar grow cdc advisori committe immun practic acip
establish rsv work group may acip make offici recommend
vaccin recommend may boost vaccin rate facilit commerci
adopt believ total address market opportun rsv vaccin elderli adult
age year older approach billion alon billion
merck commerci global pay mid-singl low-teen
percentag royalti present anticip approv
europ assum price discount europ time
approv anticip penetr reach modest
europ project merck achiev sale million billion
grow billion europ project sale million
million grow billion equat global sale million
billion billion estim could receiv royalti revenu
million million million pleas exhibit
page
unit elderli popul american yr get percent elderli per elderli sale europ elderli popul european get percent elderli per elderli sale ww elderli sale royalti royalti wholly-
cytomegaloviru cmv member herpesvirida famili cmv highli infecti
presum transmit bodili fluid infect remain system life
infect individu typic asymptomat overt diseas occur rare except
case weaken immun howev cmv particularli devast infant
suscept infect fetu infect affect neurolog develop lead
signific morbid even death approxim american women childbear age
may infect estim newborn infect birth
infant exhibit debilit defect approv cmv vaccin institut
medicin deem develop cmv vaccin high prioriti
prior cmv vaccin ineffect focus gener neutral
antibodi envelop glycoprotein gb involv infect
fibroblast result indic multipl cmv protein need incorpor
vaccin particularli gh gl five protein form
pentamer complex pc act entri vehicl infect non-fibroblast cell fulli form
pc requir train bodi gener correspond neutral antibodi
difficult construct suffici quantiti human use
engin multi-antigen mrna vaccin encod gb
five protein form pc complex vivo mous data recent publish
vaccin demonstr proprietari lnp success encapsul mrna transcript
express pc gb gener potent durabl neutral antibodi epitheli
fibroblast cell mice nhp john et al vaccin data indic mrna-
may overcom barrier prior cmv vaccin develop
conduct phase studi healthi adult volunt primari
endpoint safeti secondari endpoint assess neutral antibodi titer infect
epitheli fibroblast well presenc antigen-specif t-cell
parallel phase studi mrna target t-cell antigen cmv also
on-going expect start phase ii studi immun women childbear age
year
present anticip approv women childbear age year
 europ assum price slight discount
europ project sale million million grow
billion europ project sale million million
grow billion equat global sale million million
grow billion pleas exhibit
page
unit women child bear per cmv sale women child bear per cmv sale cmv sale second
metapneumoviru hmpv respiratori viru commonli infect children
age year symptom reminisc common cold includ nasal congest
cough sore throat headach fever typic symptom resolv
immuno-compromis patient like infant elderli risk sever lower respiratori tract
infect hmpv lead caus acut respiratori infect children
elderli individu year develop lower respiratori tract infect
rsv pneumonia approv treatment indic hmpv infect
typic manag fever medic
human parainfluenza hpiv virus caus rang respiratori ill children even
requir hospit parainfluenza viru common type hpiv
infect children year age often associ bronchiol bronchiti
pneumonia fact infect second common caus seriou acut respiratori
infect young children rsv caus estim
hospit annual adult build immun toler prior infect becom
re-infect current specif antivir treatment vaccin hpiv
multi-antigen vaccin encod viral protein associ hmpv
small percentag children immuno-compromis adult virus
caus sever respiratori infect even present co-infect rational exist
design prophylact vaccin express viral antigen build learn
multi-antigen cmv vaccin design singl vaccin compris
two mrna sequenc encod full-length protein viru protect level
neutral antibodi observ mous nhp preclin studi
initi phase dose-escal dose-select studi
studi fulli enrol healthi adult receiv two infus
vaccin four dose-escal cohort unblind result show dose toler
dose select phase continu three highest dose level evalu pend phase data
includ immunogen result anti-hmpv neutral antibodi titer
expect begin phase ib studi children year
present anticip approv europ
assum price slight discount europ project sale
million grow billion europ project sale million
grow million equat global sale million
billion billion pleas exhibit
page
zika septemb receiv million grant
barda fund vaccin formul toxicolog studi manufactur phase
develop mrna zika vaccin compani complet phase studi mrna-
healthi volunt met primari safeti endpoint though meet
immunogen endpoint dose consequ develop next-gen
demonstr greater potenc nhp challeng studi note
key differ latter formul moderna
proprietari lnp anticip phase advanc barda contract three four
barda option exercis bring total current award million
support addit phase studi late-stag advanc
chikungunya chikungunya viru spread aed
mosquito chikungunya caus varieti symptom includ joint pain fever rash
muscl pain symptom usual resolv within week symptom may last
year million infect year mainli afflict young older popul
chikungunya typic occur develop world spread part europ
 includ outbreak florida case chikungunya progress
chronic infect caus long-term symptom even death case moderna
complet phase studi healthi adult non-endem region assess
immunolog activ without bia infect studi met primari safeti
secondari immunolog endpoint follow-up continu assess antibodi persist
safeti one year second dose futur advanc program subject
separ develop therapeut antibodi prevent treat
chikungunya success complet glp toxicolog studi compani
prepar file ind conduct phase dose-rang studi healthi adult evalu
safeti toler program open ind sponsor darpa
page
neoantigen
cancer vaccin repres one earliest attempt immuno-oncolog date back
date dendreon proveng sipuleucel-t remain cancer vaccin approv
metastat castrate-resist prostat cancer mcrpc vaccin fail clinic
due insuffici induct durabl immun respons attribut
immunosuppress tumor microenviron use tumor associ antigen taa
vaccin provid adequ immunogen stimul robust t-cell activ
sever advanc relat design cancer vaccin underli technolog may help
overcom previou challeng firstli know antigen select taa tumor-
specif neoantigen two main class antigen taa express normal tissu
over-express malign cell neoantigen express malign cell make
ideal target vaccin
said develop neoantigen-bas vaccin slow identifi immunogen
neoantigen proven challeng limit efficaci next-gen cancer vaccin first
neoantigen rare tumor-sequenc mutat correspond neoantigen fact
neoantigen estim total mutat schumach et al scienc
furthermor small fraction neoantigen actual immunogen
enhanc genom profil comput algorithm improv identif neoantigen
design vaccin neoantigen rare degre immunogen
differ patient person approach move forefront higher
likelihood identifi immunogen neoantigen sequenc patient tumor
fast cheap next gen sequenc parallel increasingli sophist
comput algorithm help process enorm number tumor-sequenc mutat
order rapidli identifi neoantigen even predict one immunogen includ
vaccin
also import note human leukocyt antigen hla also known major
histocompat complex mhc consid develop cancer vaccin
person uniqu hla type translat differ prefer and/or bind affin
antigen import design cancer vaccin wherebi synthet antigen
need bind well order form antigen-mhc complex properli activ nave cell
specif mhc activ cytotox killer mhc ii activ helper t-cell
mhc type necessari sustain anti-tumor respons barrett et al clin
improv immunogen profil next-gen cancer vaccin also make ideal combin
checkpoint inhibitor induc immun respons extend durabl checkpoint
inhibitor emerg backbon i-o therapi abil take brake
immun system immunosuppress microenviron combin approach
checkpoint inhibitor mayb one day soon co-stimulatori factor cytokin expect
extend durat clinic respons seen strategi incorpor nearli
cancer vaccin clinic studi augment efficaci increas likelihood success
page
glimmer activ
clinic
earliest clinic studi neoantigen person cancer vaccin pcv report
independ trial conduct melanoma patient precursor technolog
eventu evolv ntgn cover privat
studi provid proof-of-concept neoantigen induc specif durabl t-cell
respons late stage melanoma neon studi synthet double-strand rna vaccin
design predict person tumor neoantigen demonstr respons
melanoma patient remain cancer free month vaccin ott et al
lett patient relaps experienc complet tumor regress rescu
treatment similar neoantigen vaccin form basi biontech
technolog also gener respons melanoma patient sahin et al lett
sinc public natur paper neon subsequ report preliminari phase data
lead pcv combin opdivo emso melanoma
cover also advanc pcv phase studi combin yervoy curevac
privat saw setback monotherapi metastat castrat resist prostat cancer
revis clinic strategi evalu new candid combin checkpoint
inhibitor nouscom privat also advanc pcv phase studi broad
tumor type monitor program better defin clinic activ differ neoantigen
strategi differ tumor pleas exhibit initi studi small
lack control arm clinic benefit initi report melanoma studi reinvigor
excit space believ valid mrna pcv program
initi clinic data neoantigen person cancer vaccin
opdivo
yervoy
phase iib studi mrna
base fail
mcrpc discontinu
fixvac
nsclc data
start
studi on-going
nsclc
on-going
phase start
nsclc
page
sequenc patient tumor employ proprietari genom map
technolog select person neoantigen synthes neoantigen
concatem antigen design target mhc mhc ii order elicit
t-cell respons vaccin hla type order optim antigen
present differ antigen incorpor
vaccin formul proprietari lnp administ via
intramuscular inject pcv uniqu tailor patient tumor express
neoantigen quickli synthes within matter week
lnp-encapsul pcv taken antigen present cell neoantigen
concatem transcrib ribosom result neoantigen protein chain subsequ
process neoantigen tumor-associ protein tap packag
present t-cell pleas exhibit
mechan neoantigen cancer vaccin
merck conduct phase studi
monotherapi combin keytruda resect solid tumor four escal dose
cohort assess monotherapi part
combin keytruda part novemb dlt report
evalu patient monotherapi cohort remain disease-fre
combin cohort keytruda vaccin result two partial respons
pr patient stabl diseas patient dose anticip dose
expans part studi three undisclos indic merck also begun plan
random control phase ii trial assess vaccin superior checkpoint
nation cancer institut nci also conduct separ studi nci
studi enrol advanc metastat cancer patient could see data year includ
detail character individu antigen peptid affect immun respons
page
healthi cell ra protein initi mapk signal pathway regul cell growth
differenti surviv mutat ra gene result constitut activ ra
protein abhorr cell growth ra one frequent mutat oncogen
variant kra preval follow nra hra
cancer ra mutat estim pancreat cancer colorect cancer
lung cancer associ poor prognosi resist therapi prior et al
small molecul therapeut modal capabl intracellular target ra
disappointingli small molecul unabl overcom picomolar activ gtp
bind altern alloster pocket target abrog protein-protein
interact shut ra signal howev shallow site proven nearli
imposs small molecul bind requir affin achiev therapeut effect
ra label undrugg target
emerg therapeut modal rnai capabl intracellular target
use ra rnai silenc kra suppress cell tumor growth cancer
develop silsense privat show earli sign toler efficaci
single-arm phase i/iia studi fifteen patient inoper metastat pancreat cancer
enrol receiv three dose plu chemotherapi evalu
patient median os month analysi pr
sd ct scan month therapi show increas pr rate
patient stabl diseas golan et al oncotarget phase ii studi
on-going although studi offer valid target kra variant rna-
base modal efficaci could augment select patient kra mutat
use mrna vaccin broader rang antigen
contrast inhibit knockdown kra mrna vaccin encod multipl kra
variant achiev broader activ engin encod four
common kra mutat kra variant identifi
pancreat nsclc
wang et al cancer immunol kra mutat
complet tumor-specif express healthi tissu make ideal
immunolog target wang et al present four kra variant singl
mrna exhibit stronger activ mediat ifn- anti-tumor respons vivo mous
model compar two variant kra vaccin pleas exhibit
page
approach refin select patient particular hla signatur
thought enhanc kra antigen present recent nci ran phase ii trial
demonstr cell prime target kra halt tumor growth metastat
patient subtyp day therapi durabl
month view phase ii trial encourag initi proof-of-concept moderna kra
vaccin nci also identifi enhanc anti-tumor activ kra epitop
express cancer patient subtyp correl enhanc immun
activ certain hla type valid moderna kra vaccin approach rech et al
partner merck global profit share transfer
open ind merck expect merck begin phase dose escal expans studi
intramuscular inject monotherapi combin keytruda
year believ studi could select enrol patient base kra mutat hla
subtyp furthermor agreement allow merck includ develop mrna
sting agonist futur clinic studi
present anticip reach market europ
treat kras-mut metastat pancreat cancer microsatellit instabl high msi-h
colorect cancer nsclc estim american express
express estim monthli price
europ base compar clinic data project pancreat cancer patient receiv
month therapi msi-h month therapi sinc nsclc patient live longer
estim annual price europ
project pancreat cancer sale million million
million europ project pancreat cancer sale million
million million total project global pancreat
cancer sale million million grow billion
project msi-h sale million million
million europ project msi-h sale million million
million total project global msi-h sale million
million grow million
project nsclc sale million million
million europ project nsclc sale million million
million total project global nsclc sale million
million grow billion
total project global sale million million
billion entitl half revenu million
million grow billion pleas exhibit
page
page
unit state kras-mut pancreat cancer hla treat per month month pancreat sale kras-mut pancreat cancer hla treat per month month pancreat sale pancreat sale state kras-mut msi-h hla treat per month month msi-h sale kras-mut msi-h hla treat price per month month msi-h sale msi-h sale state kras-mut hla treat price per nsclc sale kras-mut hla treat price per nsclc sale nsclc sale sale intratumor immuno-oncolog
checkpoint inhibitor specif antibodi market bristol-
myer squibb merck astrazeneca roch spark revolut i-o therapi
antibodi approv numer cancer type gener cumul sale
billion project double-digit annual growth billion
howev percentag patient achiev durabl respons checkpoint inhibitor
monotherapi reason like relat inflam hot versu non-inflam cold tumor
microenviron therapi driven drug abil potent prime mobil
t-cell block immunosuppress pathway thu therapi
effect tumor express t-cell express
import goal futur i-o therapi abil gener immune-permiss
tumor microenviron enabl infiltr activ t-cell field larg turn
combin strategi achiev therapeut goal liter hundr i-o
combin studi on-go new approv anticip variou tumor type
come year engag checkpoint target may co-express
emerg one combin strategi
cytokin therapi novel i-o approach demonstr strong mechanist potenti
synerg antibodi cancer fact high-dos first cancer
immunotherapi approv treat metastat renal cell carcinoma rcc later
melanoma cytokin initi discov garner broad investig
interest treat cancer pleiotrop effect immun cell signal prolifer howev
difficult toxic profil due short half-lif impact surviv benefit fact initi use high-dos
associ mortal rate due toxic schwartz et al oncolog
nonetheless remain target interest therapeut develop sever
compani nektar van buren design new format use
pegyl increas half-lif tune select nektar updat phase i/ii data
melanoma cohort plu opdivo show confirm orr
month median follow-up respond nine achiev cr
nektar armo bioscienc highest profil exampl cytokin combin
i-o clinic mani player develop novel cytokin therapi exampl
oncosec onc overweight develop intratumor inject plasmid
data tavo plu keytruda refractori melanoma patient show
evalu patient pr patient stabl diseas month
month one pr deepen cr
believ begin i-o cytokin combin base abil
gener adapt innat immun respons observ multi-antibodi regimen highli
refractori tumor therapeut option exist think clinic data shown
uniqu abil combin cytokin antibodi durabl deepen initi immunolog
activ tumor respons activ highli refractori popul could support acceler
approv variou tumor type ultim support adopt earlier line therapi
page
cytokin therapi compani also receiv attract valuat partnership
activ februari ahead pivot data present nektar receiv
billion up-front payment billion cash million equiti invest bristol-my
squibb expand exist collabor nektar retain strong econom global
profit share may announc billion acquisit armo bioscienc
pegilodecakin pegyl time shown phase activ monotherapi
combin chemotherapi checkpoint inhibitor across sever tumor type
develop intratumor mrna i-o therapi ligand t-cell co-
stimulatori factor select express activ effector t-cell engag
contribut prolifer t-cell may lead increas memori
popul intratumor i-o mrna incorpor microrna bind site
potenti strategi reduc off-target effect enhanc clinic toler describ
platform technolog section report
design encod formul proprietari lnp
initi encapsul candid first gener lnp revis formul
observ toxic glp tox studi preliminari safeti data phase studi
report novemb twenty-eight relapsed/refractori solid tumor patient
patient experienc grade one grade inject site reaction resolv
grade event experienc skin ulcer regress follow treatment mrna-
last dose subsequ treatment cytoxan/avastin appear caus
wound grow size led hospit event deem unrel studi drug
given pro-inflammatori target directli agon t-cell inflamm irr
like drug relat mitig dose select subsequ expans
efficaci octob show patient stabl diseas patient
progress patient ovarian cancer show regress inject lesion well
uninject lesion meet recist respons criteria base respons
plan initi phase ii cohort ovarian cancer addit expand
phase enrol recommend dose includ biopsi identifi biomark
base proof-of-concept develop tripl mrna cancer
therapi compris three mrna encod well pro-inflammatori
cytokin proprietari lnp addit pro-inflammatori cytokin
induc local innat respons may turn cold tumor hot strategi would support
combin approach checkpoint inhibitor antibodi enhanc respons
ind clear intend begin phase studi
israel year phase studi design three arm assess intratumor
inject monotherapi well combin antibodi target
dose escal conduct solid tumor lymphoma patient
plan conduct dose-expans cohort melanoma tripl neg breast
cancer tnbc head neck squamou cell carcinoma hnscc non-hodgkin lymphoma
page
present anticip gain approv europ treat
refractori melanoma tnbc hnscc given aggress prognosi refractori
melanoma tnbc project melanoma patient receiv month therapi tnbc
patient month therapi estim monthli price
europ hnscc patient project annual cost
europ
project melanoma sale million million
million europ project melanoma sale million million
million total project global melanoma sale
million million grow million
project tnbc sale million million
million europ project tnbc sale million million
million total project global tnbc sale million
million grow billion
project hnscc sale million million
million europ project hnscc sale million million
million total project global hnscc sale million
million grow billion total project global
sale million billion billion pleas exhibit
page
intratumor mrna cancer therapi partner astrazeneca
respons complet ind-en toxicolog studi support ind/cta file
packag transfer astrazeneca conduct clinic develop az plan
conduct phase studi monotherapi combin checkpoint inhibitor
year co-commerci entitl tier royalti
rang ex-u net sale respons commerci drug suppli
page
unit state relapsed/refractori checkpoint treat per month month melanoma sale relapsed/refractori checkpoint treat per month month melanoma sale melanoma sale state tripl neg breast treat per month month tnbc sale tripl neg breast treat per month month tnbc sale tnbc sale state cell carcinoma head neck treat price per head neck sale cell carcinoma head neck treat price per head neck sale head neck sale global sale ert offer proof-of-
concept mrna
orphan diseas
enzym replac therapi ert inject infus function enzym replac
defici absent protein ert address sever lysosom storag diseas includ gaucher
diseas fabri diseas mp hurler syndrom mp ii hunter syndrom
phenylketonuria pku howev challeng formul enzym durabl half-lif
result inconveni administr requir variabl dose long infus time ert
result immunogen caus develop anti-drug antibodi ada limit
effect time
mrna offer potenti address shortcom ert notabl mrna replac
extracellular protein also intracellular transmembran protein defici mrna
larg enough encod nativ full length protein reliabl gener suffici quantiti
reach therapeut level increas durat predict pharmacolog simplifi dose
easili adjust rna express transient manufactur synthet mrna offer
scalabl solut provid drug suppli chronic dose regimen requir genet orphan
diseas gene therapi edit offer potenti solut genet diseas
still carri risk insert mutagenesi may slow clinic advanc especi
mrna therapi potenti treat major defin rare diseas today
known rare diseas avail therapi mean thousand diseas million
patient current address current drug market today
develop four orphan diseas therapi howev initi clinic proof-of-concept
anticip dramat expand effort next sever year
mma inherit lysosom storag disord caus defect methylmalonyl-coenzym
mutas mut due mutat gene code mut mma occur primarili pediatr
popul afflict american european symptom present within
first month life compromis mut longer process certain metabolit
methylmalon acid lead toxic accumul hallmark diseas frequent
occurr acut metabol decompens requir hospit fatal
continu decompens lead life-long complic includ neurolog eventu
renal failur mma patient must adher strict life-long diet approv therapi
rna gene therapi candid present clinic
initi natur histori studi map studi pa patient
character diseas potenti identifi clinic endpoint biomark diseas
non-intervent studi enrol mma patient pa patient
 europ patient studi may crossov treatment studi
develop treat mma june fda grant
pediatr diseas design fda ema grant orphan drug design
intend file ind initi phase i/ii studi mma mut-
present anticip gain acceler approv
europ assum annual net price europ
project sale million million peak
million europ project sale million million
peak million total project global sale million
million grow billion pleas exhibit
page
pa anoth inherit metabol disord caus defici propionyl-coa carboxylas pcc
compris two subunit pcca pccb lie upstream mut enzym metabol
pathway mma pa occur american european children symptom
present within first month life defici pcc also lead build-up toxic
metabolit acid use
biomark similar mma frequent acut metabol decompens occur eventu
lead life-long complic includ neurolog heart diseas pa children must also
adher strict life-long diet approv therapi compani
develop treatment pa
intend file ind initi phase i/ii studi
children pa present anticip gain acceler approv
europ due ultra-orphan patient popul assum annual net
price europ project sale
million million grow million europ project mrna-
sale million million million total
project global sale million million million
page
unit mma treat price per sale mma treat price per sale sale pa treat price per sale pa treat price per sale sale phenylketonuria
pku inherit metabol disord result defici phenylalanin hydroxylas pah
inabl breakdown phenylalanin phe pku screen birth afflict
american almost european pku patient must adher sever protein-restrict
diet control phe intak high phe level result neurocognit defici
biomarin raymond develop kuvan sapropterin dihydrochlorid recent gain
approv palynziq pegvalias treat pku kuvan synthet oral formul
co-factor pah fda approv kuvan ema base phe
reduct treat patient week vs placebo kuvan gener global sale
million kuvan orphan drug exclus expir expir europ
inject palynziq approv may base phase trial
show improv phe reduct vs placebo week consensu global sale
estim palynziq million grow million howev
patient respond kuvan palynziq carri undesir side effect notabl
sever anaphylaxi leav room therapi improv pku treatment
intend file ind year conduct open-label phase studi
present anticip reach pku market
europ assum orphan price year approv per year
 slight discount europ project global sale million
million european sale peak billion pleas
fabri diseas inherit x-link lysosom storag diseas caus defect gla
gene result low activ lysosom protein alpha galactosidas alpha-g
result increas lysosom level interfer cell/tissu function
ultim lead multipl organ complic includ kidney heart sever ert
approv treat fabri diseas includ sanofi/genzym fabrazym agalsidas beta
shire shpg amsellem replag agalsidas alpha combin global sale
billion effect slow diseas progress healthi renal function never
recov alpha-g protein mimic long infus time requir
trigger unintend immune-rel side effect
intend file ind conduct open-label phase
multipl ascend dose studi fabri diseas patient
page
unit pku treat price per sale pku treat price per sale sale cardiovascular diseas
myocardi infarct heart attack occur cardiac arteri blockag result lack
oxygen death cardiomyocyt mani american suffer heart attack everi
year even individu surviv heart attack result damag heart muscl
tissu result heart failur million peopl around world
one area research turn heart function repair pathway elev vegf-a
relaxin via recombin protein therapi howev approach hinder
inabl deliv suffici therapeut concentr due inher recombin protein
instabl endogen mrna express may prove better suit deliv
adult human heart contain progenitor heart cell reprogram regener
cardiomyocyt restor cardiac function paracrin factor play key role promot
regener cardiac repair howev nativ paracrin signal proven difficult induc
therapeut benefit vegf-a paracrin factor key role promot
angiogenesi thought help regener cardiomyocyt howev previou attempt
human anim studi shown limit efficaci deliveri issu given
short half-lif vegf-a
preclin studi shown mrna encod vegf-a stimul differenti
progenitor cell cardiomyocyt precis control reduc risk side effect due
prolong vegf-a exposur zangi et al biotechnol build
initi studi mrna vegf-a optim clinic use report astrazeneca
recent public carlsson et al mol ther method clin dev result
show intracardi inject mrna transcript encod vegf-a optim elimin
need lipid encapsul improv durabl vegf-a express day
immunogen observ excitingli left ventricular eject fraction lvef mini
pig induc heart failur demonstr rescu activ two month mrna vegf-a
therapi result document first sign therapeut benefit mrna vegf-a also
mini pig heart close resembl human heart believ demonstr possibl
translat human
salin formul mrna deliv epicardi inject phase singl
ascend dose studi assess safeti intraderm infus also includ
pharmacodynam endpoint dose depend vegf-a product seen within hour
sustain hour lead stimul blood flow day singl
inject pleas exhibit intraderm inject toler
dose level mild injection-sit reaction occur one treat subject
manag lead discontinu death occur
first sign
function
therapi cardiac
page
dose depend increas vegf-a right blood phase left
astrazeneca conduct phase iia studi europ assess epicardi
inject ischem heart diseas patient cabg surgeri studi evalu
safeti toler measur chang ecg lvef astrazeneca
expect complet enrol possibl report data year
anticip gain approv europ japan base
phase iia studi design assum administ cabg patient
moder impair systol function lvef estim price per procedur
par entresto howev could prove conserv project global
sale million million grow million
entitl receiv high-singl digit royalti global sale estim
million million million pleas exhibit
page
unit arteri bypass surgeri eject fraction lvef penetr per sale arteri bypass surgeri eject fraction lvef penetr per sale arteri bypass surgeri eject fraction lvef penetr per sale sale net royalti royalti relaxin
relaxin hormon involv mainten heart function prior research shown
relaxin promot activ pathway reviv heart function damag diseas research
attempt increas relaxin level novarti acquir corthera deal worth
million relaxin therapi howev drug fail show clinic benefit phase
trial surprisingli main culprit durat action owe short half-lif
licens mrna encod relaxin protein astrazeneca
preclin data shown mark improv mrna engin relaxin
protein nhp singl inject mrna-relaxin produc function protein sustain
day compar minut observ recombin relaxin pleas exhibit
relaxin mrna sustain relaxin express day nhp
current preclin studi treat heart failur astrazeneca sponsor
phase studi assess safeti toler durat system exposur relaxin protein
partner co-commerci entitl receiv tier
mid-singl digit low royalti ou net sale
page
astrazeneca earliest pharmaceut compani partner sign
three allianc mrna candid treat cardiovascular cardiometabol diseas
cancer first agreement sign march provid exclus access select
mrna target choic period agreement az select
target vegf-a present phase iia studi treat ischem heart diseas az
enter select target relaxin preclin develop az fund develop
clinic studi respons suppli clinic product
entitl receiv tier high-singl digit royalti mid-singl digit low
royalti allianc expand az elig forti
option mrna candid
az sign new collabor two immune-oncolog mrna program
respons advanc i-o mrna candid ind-en studi az
lead clinic develop upon commerci partner share profit
cost az lead ex-u commerci elig tier double-digit
royalti ou sale thu far partner develop mrna cancer
therapi second i-o program yet announc
januari merck partner develop vaccin rsv three
undisclos virus merck subsequ disclos second vaccin varicella-zost
viru vzv chicken pox advanc two undisclos infecti diseas vaccin candid
develop respons design
manufactur mrna candid merck lead preclin clinic develop
commerci elig undisclos develop commerci
mileston plu tier mid-singl low-teen percentag royalti
merck expand allianc develop person cancer vaccin pcv
respons develop phase ii studi point
merck elect particip develop upon addit million payment
merck co-fund subsequ clinic develop partner share global
profit cost equal merck lead ex-u commerci option
co-promot
may merck agre jointli develop mrna kra vaccin
respons manufactur merck develop phase ii
point merck elect continu develop upon addit undisclos
mileston partner share global profit cost equal
june vertex enter collabor explor util mrna
produc function cftr protein cystic fibrosi therapi receiv million up-front
includ million cash million convert note elig addit
million mileston plu low- high-teen percentag royalti global sale vertex
respons develop potenti commerci mrna candid aris
agreement
page
corpor
oper
monsieur bancel serv ceo sinc prior ceo biomrieux
year serv variou role eli lilli includ manag director belgium
execut director global manufactur strategi suppli chain mssr bancel hold
master engin cole central pari ecp master scienc chemic
engin univers minnesota earn harvard busi school
dr hoge serv presid charg mrna technolog platform therapeut area
research pre-clin develop prior join dr hoge
healthcar practic mckinsey compani hold univers california
san francisco neurosci amherst colleg
dr mendlein serv presid corpor product strategi recent john
execut chairman ceo atyr pharma john chairman ceo
acquir debiopharm ceo adnexu
acquir bristol-my squibb gener counsel chief knowledg offic
aurora bioscienc acquir dr mendlein hold
ph physiolog biophys ucla univers california hast
colleg law biolog univers miami
dr zak serv prior dr zak serv svp head global oncolog
sanofi dr zak start industri glaxosmithklin built oncolog translat
medicin team led develop lapatinib foretinib dr zak associ professor
medicin univers pennsylvania dr zak receiv ph
gurion univers israel conduct post-doctor research nih complet
clinic train intern medicin templ univers hospit follow fellowship
medic oncolog univers pennsylvania
dr serv moderna cfo prior lorenc manag director co-head
invest bank goldman sach dr hold univers pennsylvania
school medicin wharton school busi earn biochem
scienc harvard univers
mr andr serv chief technic oper qualiti offic
respons manufactur preclin clinic develop program prior
global head technic oper novarti work year
mr andr hold master pharmaci alcala de henar univers madrid
mr damiani serv chief digit offic prior work biomrieux
motorola hold master scienc degre inform system architectur
univers toulous franc earn execut joint program
london school econom new york univers stern busi school hec school
manag pari
page
recogn revenu partnership astrazeneca merck vertex well
grant collabor revenu million million first
month forecast collabor revenu million million
grant revenu million million first month
forecast grant revenu million million
 invest million million first month
project invest million million compani
advanc mrna candid clinic
sg expens million million first month
project compani spend million grow million
report net loss million per share includ prefer share
dividend million first month project net
loss million million
end cash billion decemb issu million
share rais gross ipo proce million estim hold pro
forma cash billion million share outstand
risk associ common drug discovery/develop compani
includ clinic regulatori commerci mrna novel technolog limit clinic
experi vaccin cancer orphan diseas cardiovascular diseas competit field
vaccin therapi may fail clinic gain regulatori approv mrna
drug may achiev sale forecast may requir invest
project compani exist partnership may falter unabl sign new collabor
may unabl file new ind advanc mrna candid clinic
may requir addit capit could face futur litig
page
thousand except per share data
prefer share dividend redempt valu
net loss attribut common sharehold
compani report piper jaffray estim
current disclosur inform compani found
